Stocktoria
Century Therapeutics, Inc. IPSC
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-17
Century Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $109.2M | $6.6M | $2.2M | $5.2M | — | — |
| R&D expense | — | — | — | — | $75.6M | $39.7M |
| Operating income | -$17.3M | -$138.1M | -$146.5M | -$133.8M | -$94.9M | -$53.9M |
| Interest expense | — | — | $540,000 | $1.0M | $1.3M | $381,000 |
| Income tax | -$68,000 | $1.8M | $1.9M | $91,000 | $43,000 | — |
| Net income | -$9.6M | -$126.6M | -$136.7M | -$130.9M | -$95.8M | -$53.6M |
| EPS (diluted) | $-0.14 | $-1.61 | $-2.30 | $-2.96 | $-2.96 | $-7.16 |
| Operating cash flow | -$103.9M | -$110.1M | -$88.3M | $14.1M | -$89.0M | -$41.3M |
| Free cash flow | -$104.7M | -$110.3M | -$102.1M | -$16.6M | -$134.0M | -$51.1M |
| Cash & equivalents | $61.9M | $58.4M | $47.3M | $84.3M | $56.4M | $27.2M |
| Total assets | $223.7M | $353.2M | $360.7M | $486.5M | $437.4M | $106.8M |
| Total liabilities | $64.8M | $191.9M | $175.9M | $183.8M | $41.1M | $33.4M |
| Shareholders' equity | $158.9M | $161.4M | $184.8M | $302.7M | $396.2M | -$106.4M |
Growth · year-over-year · Revenue CAGR 175.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +1556.8% | +194.8% | -57.0% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.